Blog
RSS FeedPosted by Michael Wonder on 17 Mar 2022
ICER publishes evidence report on novel agents to prevent chemotherapy-induced neutropenia and other myelosuppressive effects
17 March 2022 - Due to the FDA action on plinabulin, ICER will not hold a public meeting but has produced ...
Posted by Michael Wonder on 16 Mar 2022
ICER publishes research protocol for assessing price increases of prescription drugs in California
16 March 2022 - Final assessment to be published on 13 October; drugs to be evaluated are those identified through California’s ...
Posted by Michael Wonder on 08 Mar 2022
ISPOR launches “About Real-World Evidence” content
8 March 2022 - Introductory information is designed to make RWE more accessible for health care audiences. ...
Posted by Michael Wonder on 03 Mar 2022
ICER to assess treatments for obesity management
3 March 2022 - Report will be subject of New England CEPAC meeting in September 2022; draft scoping document open ...
Posted by Michael Wonder on 03 Mar 2022
ICER to develop a California state unsupported price increase report funded by the California Health Care Foundation
3 March 2022 - Expanded funding supports the development of two annual “Unsupported Price Increase” reports specific to drugs identified through ...
Posted by Michael Wonder on 15 Feb 2022
ICER publishes final evidence report and policy recommendations on tirzepatide for type 2 diabetes
15 February 2022 - Independent appraisal committee found that evidence is adequate to demonstrate a net health benefit of tirzepatide added ...
Posted by Michael Wonder on 10 Feb 2022
A new way to contain unaffordable medication costs - exercising the Government’s existing rights
9 February 2022 - Existing laws could be used to help make many drugs more affordable. ...
Posted by Michael Wonder on 07 Feb 2022
Why so few value assessments on health services and procedures, and what should be done?
4 February 2022 - The field of cost effectiveness analysis has grown rapidly but in somewhat lopsided fashion. ...
Posted by Michael Wonder on 05 Feb 2022
Price of COVID treatments from Pfizer, Merck, GSK align with patient benefits
3 February 2022 - The prices of drugs used to treat COVID-19 for those at risk of serious illness are ...
Posted by Michael Wonder on 03 Feb 2022
ICER releases draft evidence report on treatments for COVID-19
3 February 2022 - Public comment period now open until 3 March 2022; requests to make oral comment during public ...
Posted by Michael Wonder on 03 Feb 2022
ICER to assess treatments for amyotrophic lateral sclerosis
3 February 2022 - Report will be subject of Midwest CEPAC meeting in August 2022; draft scoping document open to ...
Posted by Michael Wonder on 27 Jan 2022
The certainty of uncertainty in health technology assessment
26 January 2022 - History is replete with stories of poor decisions—catastrophes that leaders might have averted, and great opportunities that ...
Posted by Michael Wonder on 25 Jan 2022
ICER releases draft evidence report on novel agents to prevent chemotherapy-induced neutropenia
25 January 2022 - Registration now open for 1 February “Early Insights” webinar. Public comment period now open until 22 ...
Posted by Michael Wonder on 06 Jan 2022
ICER publishes evidence report on tirzepatide for type 2 diabetes
6 January 2022 - Tirzepatide has a novel dual GIP and GLP-1 receptor agonist mechanism of action and is seen as ...
Posted by Michael Wonder on 28 Dec 2021
ICER to assess treatments for Alzheimer’s disease
22 December 2021 - Report will be subject of CTAF meeting in July 2022; draft scoping document open to public ...